Round up.

Abstract

Sitravatinib inhibits angiogenesis and mitigates immunosuppressive effects in the tumor microenvironment (TME), thereby improving the efficacy of immune checkpoint inhibitors by producing a less immunosuppressive TME.[1] In this single-arm, interventional, phase 2 study, neoadjuvant sitravatinib in combination with nivolumab was administered to 17 patients with T2b–T3a clear cell renal cell carcinoma.[2] The median follow-up was 26 months. The objective response rate was 11.8% with two radiologic partial responses, and 88.2% (n = 15) had stable disease. No patient experienced progressive disease before surgery or an increase in lesion size; the median observed tumor shrinkage was 13.5% (range: 0%–33%). The estimated 12-month disease-free survival (DFS) probability was 94% (95% confidence interval [CI], 65–99); the estimated 24-month DFS probability was 88% (95% CI, 61–97). There were no grade 4/5 treatment-related adverse events. Correlative blood and tissue analyses showed changes in the TME, resulting in an immunologically active tumor by the time of surgery (median time to surgery was 50 days).